Guide to the efficacy and correct use of giritinib

Gilteritinib (Gilteritinib), its trade name is Xospata or Xegatan, is an oral selective FLT3 kinase inhibitor. The drug is designed for patients with relapsed or refractory acute myeloid leukemia (AML) who carry FLT3 mutations. As the world's first drug approved for this type of disease, giritinib has demonstrated remarkable results in clinical treatment, bringing new treatment prospects to patients.

1. Function and efficacy

Giritinib is not only effective against FLT3-ITD mutations, but also inhibits FLT3-TKD mutation, and more excitingly, it even inhibits the AXL kinase associated with resistance to FLT3 inhibitors. This dual inhibitory property gives giritinib a significant advantage in the treatment of FLT3 mutation-positive AML. Multiple clinical trial data show that giritinib can significantly extend the overall survival and progression-free survival of patients, improve the response rate, and bring better prognosis to patients.

2. Correct usage guide

1. Dose and frequency: The recommended starting dose of gilitinib is 120mg per day, administered orally, and only needs to be taken once a day. To keep blood levels stable, patients should take the drug at approximately the same time every day. Tablets should be swallowed whole and not broken, crushed or chewed to ensure complete release and absorption of the drug.

2. Taking tips: Giritinib can be taken with food or on an empty stomach. However, in order to improve the absorption effect of the drug, it is recommended to take it with food with high fat content. Simply swallow the tablet whole with a glass of water.

3. Response to missed doses: If a dose is missed, the patient should take it as soon as possible on the same day, but the interval between two doses should not be less than 12 hours. If the missed dose is close to the time of the next dose, there is no need to take it again and you can just continue taking the medicine as originally planned.

3. Precautions for use

1. Side effect monitoring: During the use of giritinib, patients should pay close attention to their body’s reaction. If common side effects such as nausea, vomiting, diarrhea, fatigue, etc. occur, you should inform your doctor in time and follow the doctor's instructions. For serious adverse reactions, such as allergic reactions, difficulty breathing, etc., the drug should be stopped immediately and seek medical treatment.

2. Regular follow-up examinations: Patients should go to the hospital regularly for follow-up examinations, including monitoring of liver function, blood routine and other items, to evaluate the effects of treatment and the impact of drugs on the body.

3. Avoid drug interactions: When using gilitinib, your doctor should be informed of all medications you are taking (including prescription drugs, over-the-counter drugs, vitamins, and herbal supplements) to avoid the potential risks of drug interactions.

In summary, giritinib, as an innovative targeted drug, provides an effective treatment option for FLT3 mutation-positive AML patients. When using giritinib, patients should strictly follow the doctor's instructions and instructions to ensure the safety and effectiveness of the medication. At the same time, paying close attention to the body's reaction and regular follow-up examinations are also important to ensure the effectiveness of treatment.